ABBV-579
- Generic Name
- ABBV-579
First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors
Phase 1
Recruiting
- Conditions
- Advanced Solid Tumors Cancer
- Interventions
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- Calico Life Sciences LLC
- Target Recruit Count
- 263
- Registration Number
- NCT04417465
- Locations
- 🇺🇸
Highlands Oncology Group Springdale, Springdale, Arkansas, United States
🇺🇸Yale University, New Haven, Connecticut, United States
🇺🇸Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath